Literature DB >> 21088912

Comparison of 7-day and repeated 24-h recall of type 2 diabetes.

A V Bennett1, D L Patrick, D M Bushnell, C F Chiou, P Diehr.   

Abstract

PURPOSE: Patient reporting of type 2 diabetes symptoms in a questionnaire with a 7-day recall period was expected to be different from symptom reports using a 7-day diary with repeated 24-h recall based on cognitive theory of memory processes and prior literature. This study compared these two types of recall in patients diagnosed with type 2 diabetes (T2D).
METHODS: One hundred and forty adults with T2D completed a daily diary for 7 days containing 9 T2D-related symptom and impact items. On day 7, patients completed the same items with a 7-day recall period. We examined the concordance of 7-day recall with summary descriptors of the daily reports and compared the scores and the discriminant ability of 7-day recall and mean of daily reports.
RESULTS: Seven-day recall was most concordant with the mean of daily reports. The average difference in scores was small (range 0.22-0.77 on 11-point scale) and less than 0.5 standard deviations. For some items, the difference was positively associated with the variation in daily reports. The discriminant ability was comparable.
CONCLUSIONS: In this study population, a questionnaire with 7-day recall provided information consistent with a daily diary measure of the average week-long experience of T2D symptoms and impacts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088912     DOI: 10.1007/s11136-010-9791-5

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  17 in total

1.  Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation.

Authors:  R A Deyo; P Diehr; D L Patrick
Journal:  Control Clin Trials       Date:  1991-08

2.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

3.  Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis.

Authors:  Antonia V Bennett; Donald L Patrick; James F Lymp; Todd C Edwards; Christopher H Goss
Journal:  J Cyst Fibros       Date:  2010-12       Impact factor: 5.482

4.  Voiding and incontinence frequencies: variability of diary data and required diary length.

Authors:  Yukio Homma; Takashi Ando; Masaki Yoshida; Shinji Kageyama; Mineo Takei; Kosuke Kimoto; Osamu Ishizuka; Momokazu Gotoh; Tatsuru Hashimoto
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

5.  Development of a type 2 diabetes symptom checklist: a measure of symptom severity.

Authors:  P A Grootenhuis; F J Snoek; R J Heine; L M Bouter
Journal:  Diabet Med       Date:  1994-04       Impact factor: 4.359

6.  Recall bias for seven-day recall measurement of alcohol consumption among emergency department patients: implications for case-crossover designs.

Authors:  Gerhard Gmel; Jean-Bernard Daeppen
Journal:  J Stud Alcohol Drugs       Date:  2007-03       Impact factor: 2.582

7.  Understanding recall of weekly pain from a momentary assessment perspective: absolute agreement, between- and within-person consistency, and judged change in weekly pain.

Authors:  Arthur A Stone; Joan E Broderick; Saul S Shiffman; Joseph E Schwartz
Journal:  Pain       Date:  2004-01       Impact factor: 6.961

8.  Comparison of "subjective" and "objective" measures of severity of urinary incontinence in women. Program for Women Research Group.

Authors:  D M Elser; J A Fantl; D K McClish
Journal:  Neurourol Urodyn       Date:  1995       Impact factor: 2.696

9.  Does the peak-end phenomenon observed in laboratory pain studies apply to real-world pain in rheumatoid arthritics?

Authors:  A A Stone; J E Broderick; A T Kaell; P A DelesPaul; L E Porter
Journal:  J Pain       Date:  2000       Impact factor: 5.820

Review 10.  Recommendations on health-related quality of life research to support labeling and promotional claims in the United States.

Authors:  D A Revicki; D Osoba; D Fairclough; I Barofsky; R Berzon; N K Leidy; M Rothman
Journal:  Qual Life Res       Date:  2000       Impact factor: 3.440

View more
  7 in total

1.  Comparison of seven-day and repeated 24-hour recall of symptoms in the first 100 days after hematopoietic cell transplantation.

Authors:  William A Wood; Allison M Deal; Antonia V Bennett; Sandra A Mitchell; Amy P Abernethy; Ethan Basch; Charlotte Bailey; Bryce B Reeve
Journal:  J Pain Symptom Manage       Date:  2014-08-13       Impact factor: 3.612

Review 2.  Ambulatory and diary methods can facilitate the measurement of patient-reported outcomes.

Authors:  Stefan Schneider; Arthur A Stone
Journal:  Qual Life Res       Date:  2015-06-23       Impact factor: 4.147

3.  Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.

Authors:  Tito R Mendoza; Amylou C Dueck; Antonia V Bennett; Sandra A Mitchell; Bryce B Reeve; Thomas M Atkinson; Yuelin Li; Kathleen M Castro; Andrea Denicoff; Lauren J Rogak; Richard L Piekarz; Charles S Cleeland; Jeff A Sloan; Deborah Schrag; Ethan Basch
Journal:  Clin Trials       Date:  2017-03-20       Impact factor: 2.486

4.  Patient demographic and psychosocial characteristics associated with 30-day recall of self-reported lower urinary tract symptoms.

Authors:  Kathryn E Flynn; Sarah A Mansfield; Abigail R Smith; Brenda W Gillespie; Catherine S Bradley; David Cella; Margaret E Helmuth; H Henry Lai; Ziya Kirkali; Pooja Talaty; James W Griffith; Kevin P Weinfurt
Journal:  Neurourol Urodyn       Date:  2020-07-23       Impact factor: 2.696

5.  Temporal trends in symptom experience predict the accuracy of recall PROs.

Authors:  Stefan Schneider; Joan E Broderick; Doerte U Junghaenel; Joseph E Schwartz; Arthur A Stone
Journal:  J Psychosom Res       Date:  2013-07-06       Impact factor: 3.006

6.  Diet Quality Indices and Their Correlation with Glycemic Status and Lipid Profile in Patients with Type 2 Diabetes.

Authors:  Roxaneh Sadat Ziaee; Parisa Keshani; Moosa Salehi; Haleh Ghaem
Journal:  Adv Prev Med       Date:  2021-03-06

7.  Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer.

Authors:  Elisabeth M Schaffer; Ethan M Basch; Gisela M Schwab; Antonia V Bennett
Journal:  Clin Trials       Date:  2021-04-22       Impact factor: 2.486

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.